pharmacopeia
GET
/api/v1/drug/fexofenadine
2D structure
2-[4-[1-hydroxy-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butyl]phenyl]-2-methylpropanoic acid
SMILES CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O
InChIKey RWTNPBWLLIMQHL-UHFFFAOYSA-N

Mechanism of action

Sourced from openFDA

Mechanism-of-action class: Histamine H1 Receptor Antagonists.

Histamine H1 Receptor

Indications

Sourced from openFDA
  • Uses reduces hives and relieves itching due to hives (urticaria). This product will not prevent hives or an allergic skin reaction from occurring.

Dosage & administration

Sourced from openFDA

Directions adults and children 12 years of age and over: take one 180 mg tablet with water every once a day; do not take more than 1 tablet in 24 hours children under 12 years of age: do not use adults 65 years of age and older: ask a doctor consumers with kidney disease: ask a doctor

Warnings & precautions

Sourced from openFDA

Severe Allergy Warning: Get emergency help immediately if you have hives along with any of the following symptoms:  trouble swallowing  dizziness or loss of consciousness  swelling of tongue  swelling in or around mouth  trouble speaking  wheezing or problems breathing  drooling These symptoms may be signs of anaphylactic shock. This condition can be life threatening if not treated by a health professional immediately. Symptoms of anaphylactic shock may occur when hives first appear or up to a few hours later

Approval history

Sourced from openFDA
  • Dec 24, 1997NDANDA020786Chattem Sanofi
  • Feb 25, 2000NDANDA020872Chattem Sanofi
  • Oct 19, 2004NDANDA021704Chattem Sanofi
  • Sep 1, 2005ANDAANDA076447Teva
  • Apr 11, 2006ANDAANDA076502Dr Reddys Labs Ltd
  • Jul 26, 2007NDANDA021909Chattem Sanofi
  • Mar 17, 2010ANDAANDA079043Dr Reddys Labs Ltd
  • Jan 24, 2011NDANDA201373Chattem Sanofi

FAERS reports

View JSON
Reference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. Counts reflect reporting volume — how often a reaction was reported, not how often it occurs. For decision-grade use, consult openFDA and the FAERS Public Dashboard directly.
23,411 total reports matchedLatest report Share = reports listing the reaction ÷ total matched reports. Rows can sum to >100% because a single report often lists multiple reactions.
  1. 1Drug Ineffective4,02817%
  2. 2Headache1,0224.4%
  3. 3Fatigue1,0194.4%
  4. 4Nausea9444.0%
  5. 5Pruritus8903.8%
  6. 6Extra Dose Administered8623.7%
  7. 7No Adverse Event8593.7%
  8. 8Diarrhoea8273.5%
  9. 9Dizziness7933.4%
  10. 10Dyspnoea7203.1%
  11. 11Rash7063.0%
  12. 12Somnolence6812.9%
  13. 13Cough6412.7%
  14. 14Insomnia6102.6%
  15. 15Pain5792.5%

Clinical trials

View JSON

The 10 most recently updated of 109 ClinicalTrials.gov registrations naming Fexofenadine as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

Frequently asked questions

How does Fexofenadine work?
Mechanism-of-action class: Histamine H1 Receptor Antagonists.
What is Fexofenadine used for?
According to FDA labeling, Fexofenadine carries indications including: Uses reduces hives and relieves itching due to hives (urticaria). This product will not prevent hives or an allergic skin reaction from occurring.. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.
What class of drug is Fexofenadine?
Fexofenadine is classified as Other antihistamines for systemic use, Histamine-1 Receptor Antagonist, Histamine H1 Receptor Antagonists, Decreased Histamine Activity.
What are the brand names for Fexofenadine?
Fexofenadine is marketed under brand names including Allegra, Allegra-D, Wal-Fex, Wal-Fex D.
Note. Data for fexofenadine is illustrative MVP content compiled from public sources. pharmacopeia is for educational and informational use only and is not a substitute for professional medical advice.

Search pharmacopeia

Search drugs, classes, and ingredients